Lyell’s Ronde-Cel Shows Strong Safety Profile in Large B-Cell Lymphoma Trials — Lyell Immunopharma, Inc.

Event summary

Lyell Immunopharma presented updated safety data for Ronde-Cel in 108 patients with relapsed/refractory large B-cell lymphoma (LBCL) at EHA 2026.
No Grade ≥ 3 cytokine release syndrome (CRS) events reported, supporting outpatient administration.
Translational data highlight enhanced memory potential of cytotoxic effector cells due to CD62L+ enrichment and CD19/CD20 dual-targeting.
PiNACLE pivotal trial data update expected in H2 2026, with BLA submission targeted for H2 2027.

The big picture

Lyell’s Ronde-Cel is positioning itself as a next-generation CAR T-cell therapy with a differentiated safety profile and durable responses. The data presented at EHA 2026 reinforce its potential in the competitive LBCL market, particularly in the 3L+ setting where unmet needs remain high. The upcoming PiNACLE trial results will be critical in determining its regulatory and commercial trajectory.

What we're watching

Regulatory Pathway: Whether the PiNACLE trial data in H2 2026 will support a smooth BLA submission in H2 2027.
Competitive Positioning: How Ronde-Cel’s safety and efficacy profile will compare against approved CAR T-cell therapies like axicabtagene ciloleucel and lisocabtagene maraleucel.
Manufacturing Scalability: The pace at which Lyell can scale manufacturing to meet potential commercial demand post-approval.